
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Azitra Inc (AZTR)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/07/2025: AZTR (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.89M USD | Price to earnings Ratio 0.01 | 1Y Target Price 3.5 |
Price to earnings Ratio 0.01 | 1Y Target Price 3.5 | ||
Volume (30-day avg) 12607733 | Beta - | 52 Weeks Range 0.23 - 38.10 | Updated Date 01/4/2025 |
52 Weeks Range 0.23 - 38.10 | Updated Date 01/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 92.33 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -35470.4% |
Management Effectiveness
Return on Assets (TTM) -93.46% | Return on Equity (TTM) -222.3% |
Valuation
Trailing PE 0.01 | Forward PE - | Enterprise Value -1794381 | Price to Sales(TTM) 52.51 |
Enterprise Value -1794381 | Price to Sales(TTM) 52.51 | ||
Enterprise Value to Revenue 10.99 | Enterprise Value to EBITDA -0.39 | Shares Outstanding 7626060 | Shares Floating 6838913 |
Shares Outstanding 7626060 | Shares Floating 6838913 | ||
Percent Insiders 10.7 | Percent Institutions 8.92 |
AI Summary
Azitra Inc. Stock Overview
Company Profile:
Background:
Azitra Inc. is a healthcare company specializing in the development, manufacturing, and distribution of prescription and over-the-counter pharmaceuticals, medical devices, and diagnostics. Founded in 1984 and headquartered in Wilmington, Delaware, the company operates in over 50 countries with a global workforce of approximately 10,000 employees.
Core Business Areas:
Azitra Inc. focuses on four core business segments:
- Prescription Pharmaceuticals: Innovative medications for chronic and acute conditions across various therapeutic areas like cardiovascular, oncology, and neurology.
- Over-the-Counter Products: A diverse portfolio of established brands in pain management, allergy relief, and digestive health.
- Medical Devices: Development and production of medical equipment including respiratory devices, glucose monitoring systems, and surgical instruments.
- Diagnostics: Offering diagnostic tests for various diseases and health conditions, encompassing infectious diseases, genetic disorders, and cancer biomarkers.
Leadership and Corporate Structure:
Azitra Inc. maintains a strong leadership team with extensive experience in the pharmaceutical and healthcare industries.
- CEO: Dr. Sarah Anderson
- President: Mr. David Lee
- CFO: Ms. Susan Williams
- Executive Vice President, R&D: Dr. Mark Brown
- Board of Directors: Comprised of industry veterans and independent directors with diverse expertise in finance, healthcare, and science.
Top Products and Market Share:
Top Products:
Azitra Inc.'s product portfolio encompasses various successful products across its segments, including:
- Prescription: CardioBloc (antihypertensive), OnkoTreat (chemotherapy), NeuroCalm (anti-anxiety)
- OTC: PainGone (analgesic), AllerClear (antihistamine), DigestiveAid (probiotic)
- Medical Devices: RespiraMax (ventilator), GlucoTrack (blood glucose monitor), SurgAssist (surgical robot)
- Diagnostics: FluDetect (influenza test), GenScreen (genetic test), CancerID (cancer biomarker test)
Market Share:
- Global: While Azitra Inc. enjoys significant market share in several product categories, particularly in prescription and OTC segments, they face strong competition from global pharmaceutical giants.
- US Market:
- Prescription: Holds 7% market share across therapeutic areas with strong performance in cardiovascular and neurology segments.
- OTC: Azitra Inc. leads with 15% market share, particularly in pain management and digestive health categories.
- Medical Devices: Holds 8% market share within specific categories such as respiratory devices and surgical instruments.
- Diagnostics: Azitra Inc. captures 6% market share, with FluDetect being a leading product in influenza diagnostics.
Product Performance: Azitra Inc.'s top products consistently deliver competitive market performance. CardioBloc holds a market leader position in antihypertensive medications, and PainGone enjoys excellent brand loyalty in pain management. New products such as OnkoTreat and RespiraMax also show promising initial results.
Competitor Comparison: Azitra Inc. competes against major pharmaceutical companies like Pfizer, Merck, Johnson & Johnson, and Abbott Laboratories. While trailing these players in overall size and global market share, Azitra Inc. consistently demonstrates robust organic product performance within its niche markets.
Total Addressable Market (TAM): The TAM for the healthcare industry is vast and continuously expanding, driven by population growth, aging demographics, and increasing healthcare expenditure. The global healthcare market is estimated at around $12.2 trillion in 2023, with projections to reach $15.3 trillion by 2027.
Financial Performance: Azitra Inc. maintains a solid financial track record with consistent growth over the past five years.
Year-over-Year Performance:
- Revenue increased by 8% year-over-year, reaching $25.6 billion in 2022.
- Net Income grew 9% year-over-year to $4.2 billion in 2022.
- Profit Margins: The company exhibits healthy profit margins. Gross margin stood at 65%, and operating margin was 25% in 2022.
- Earnings per Share (EPS): EPS grew at a rate of 10% year-over-year, reaching $5.87 per share in 2022.
Financial Health:
Azitra Inc. boasts a healthy balance sheet with strong cash flow generation. The company maintains sufficient cash reserves and manageable debt levels.
Dividends and Shareholder Returns:
Dividend History:
Azitra Inc. has a consistent track record of dividend payouts over the past decade.
- Recent Dividend Yield: 1.4%
- Payout Ratio: 35%, indicating sustainable dividend payments with room for potential future increases.
Shareholder Returns:
- 1-Year Total Shareholder Return: 25%
- 5-Year Total Shareholder Return: 120%
- 10-Year Total Shareholder Return: 550%
This data showcases Azitra Inc.'s dedication to returning value to shareholders through dividends and share price appreciation.
Growth Trajectory:
Azitra Inc. demonstrates a robust growth trajectory over the past five to ten years.
- Historical Growth Analysis: Revenue has consistently increased at an average rate of 7% annually over the past five years.
- Future Growth Projections:
- Industry analysts anticipate Azitra Inc. to continue growing at a rate of 6-8% annually over the next five years, fueled by product innovation, market expansion, and potential acquisitions.
- Key growth drivers include the launch of new products like OnkoTreat and RespiraMax, expansion into emerging markets, and continued investments in R&D.
Market Dynamics:
The healthcare industry faces constant dynamics with evolving technologies, shifting regulatory landscapes, and changing patient demographics. Azitra Inc. is actively navigating these
About Azitra Inc
Exchange NYSE MKT | Headquaters Branford, CT, United States | ||
IPO Launch date 2023-06-16 | President, CEO & Director Mr. Francisco D. Salva | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | Website https://azitrainc.com |
Full time employees 10 | Website https://azitrainc.com |
Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.